HIV/AIDS clinics and hospitals that participate in the 340B program are condemning drug manufacturer Gilead’s new conditions on 340B pricing on its branded hepatitis C treatments when covered entities use contract pharmacies.
HIV/AIDS clinics and hospitals that participate in the 340B program are condemning drug manufacturer Gilead’s new conditions on 340B pricing on its branded hepatitis C treatments when covered entities use contract pharmacies.
*Sign up for news summaries and alerts from 340B Report